One analyst reiterated his pessimistic view of the pharmaceutical titan's future.

By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for ...

The healthcare stock looks ridiculously undervalued.

The news is the latest example of the biotech industry's struggles in the Bay Area.

Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines ...

Good news has been scarce for this beaten-down drugmaker.

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

Doctors break down what you need to know about the four-dose vaccine.